Program
Metformin
Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.
Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 290 open or running | phase 3since Nov 9, 2005 | Nov 9, 2005 | none ahead |
| Merckits history only | 190 open or running | phase 4since Oct 9, 2009 | Feb 15, 2005 | none ahead |
| Sanofiits history only | 160 open or running | phase 4since Jul 28, 2006 | Sep 30, 2002 | none ahead |
| GlaxoSmithKlineits history only | 140 open or running | phase 4since Oct 17, 2005 | Sep 3, 2003 | none ahead |
| Takedaits history only | 120 open or running | phase 4since Sep 17, 2008 | Jul 30, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 90 open or running | phase 4since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| Teva Pharmaceutical Industriesits history only | 90 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatrisits history only | 80 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| ADIUMits history only | 70 open or running | no phasesince Jun 3, 2026 | Jun 3, 2026 | none ahead |
| LG Chemits history only | 70 open or running | phase 3since Feb 6, 2013 | Aug 22, 2011 | none ahead |
| Novartisits history only | 70 open or running | phase 4since Aug 28, 2010 | Jul 31, 2008 | none ahead |
| Elcelyx Therapeuticsits history only | 60 open or running | phase 2since Aug 1, 2012 | Aug 1, 2012 | none ahead |
| Torrent Pharmaceuticalsits history only | 60 open or running | phase 1since Jul 21, 2009 | Jul 21, 2009 | none ahead |
| Dong Wha Pharmaceuticalits history only | 50 open or running | phase 1since Aug 5, 2014 | Aug 5, 2014 | none ahead |
| Bristol-Myers Squibbits history only | 40 open or running | phase 4since Oct 22, 2008 | May 3, 2002 | none ahead |
| Joint Stock Company "Farmak"its history only | 40 open or running | phase 1since Nov 8, 2021 | Nov 8, 2021 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 40 open or running | phase 4since Jul 15, 2009 | Jul 15, 2009 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Dec 15, 2008 | Jan 25, 2006 | none ahead |
| Gedeon Richter Plc.its history only | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Sun Pharmaceutical Industriesits history only | 30 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| AET Laboratories Privateits history only | 20 open or running | no phasesince Mar 25, 2022 | Mar 25, 2022 | none ahead |
| AgelessRxits history only | 21 open or running | phase 3since Dec 18, 2024 | Oct 26, 2020 | none ahead |
| Aspargo Labsits history only | 22 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | none ahead |
| Biocineseits history only | 20 open or running | phase 4since Jun 2, 2011 | Apr 27, 2011 | none ahead |
| Boryung Pharmaceuticalits history only | 22 open or running | phase 1since Jul 16, 2025 | Jul 16, 2025 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Geropharmits history only | 20 open or running | phase 1since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Handokits history only | 20 open or running | phase 4since Sep 21, 2011 | Sep 21, 2011 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 3since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| NuSirt Biopharmaits history only | 20 open or running | phase 2since May 28, 2014 | May 28, 2014 | none ahead |
| Bio-innovaits history only | 11 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 3since Jul 9, 2012 | Jul 9, 2012 | none ahead |
| Cortendo ABits history only | 10 open or running | phase 1since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| Dalim BioTechits history only | 10 open or running | phase 1since Jan 29, 2013 | Jan 29, 2013 | none ahead |
| Disphar Internationalits history only | 10 open or running | phase 1since Aug 14, 2014 | Aug 14, 2014 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| Hamad Medicalits history only | 10 open or running | no phasesince Apr 19, 2021 | Apr 19, 2021 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Jan 23, 2013 | Jan 23, 2013 | none ahead |
| Health Clinicsits history only | 10 open or running | phase 3since Jul 22, 2014 | Jul 22, 2014 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Sep 15, 2010 | Sep 15, 2010 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 3since Nov 19, 2010 | Nov 19, 2010 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| Ozmosis Researchits history only | 10 open or running | phase 2since Feb 18, 2011 | Feb 18, 2011 | none ahead |
| PT. Pyridam Farma Tbkits history only | 10 open or running | no phasesince Feb 12, 2023 | Feb 12, 2023 | none ahead |
Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Oct 5, 2015.
- Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
- Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06792968 · 64 enrolled · Russian Federation
- Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06823856 · 64 enrolled · Russian Federation
- Feb 19, 2025Nabiqasim Industries (Pvt)’s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
- Jul 16, 2025Boryung Pharmaceutical’s first studies: 2 phase 1 studies in Diabetes MellitusNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07083401, NCT07083388
- Aug 12, 2025Phase 1 study in HealthyMerck · NCT07121959 · 14 enrolled · United States
- Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
- Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
- Dec 10, 2025Aspargo Labs’ first studies: 2 phase 1 studies in Healthy VolunteerNew to Aspargo LabsAspargo Labs · NCT07300033, NCT07300020
- Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
- Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
- Apr 7, 2026Phase 1 study in HealthyMerck · NCT07530289 · 12 enrolled · United States
- Jun 3, 2026ADIUM’s first studies: 3 no phase studies in Bioequivalence Study in Healthy SubjectsNew to ADIUMADIUM · NCT07633054, NCT07633041, NCT07633028
- Aug 10, 20264 no phase studiesADIUM · NCT07763964, NCT07763951, NCT07763912 and 1 more
TargetBeta
“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 215 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07763964Bioequivalance · Mexico | – | Completed | ADIUM | Dec 19, 2025 | 46 |
| NCT07763951Bioequivalance · Mexico | – | Completed | ADIUM | Dec 14, 2025 | 46 |
| NCT07763912Bioequivalence · Mexico | – | Completed | ADIUM | Dec 5, 2025 | 46 |
| NCT07763899Bioequivalance · Mexico | – | Completed | ADIUM | Nov 30, 2025 | 46 |
| NCT07633054Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Nov 24, 2025 | 42 |
| NCT07633041Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 4, 2025 | 42 |
| NCT07633028Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 8, 2025 | 42 |
| NCT07530289Healthy · United States | 1 | Completed | Merck | May 23, 2026 | 12 |
| NCT07396844Fasting · Thailand | 1 | Completed | LG Chem | Jun 26, 2026 | 28 |
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | LG Chem | Feb 6, 2026 | 58 |
| NCT07300033Healthy Volunteer | 1 | Not yet recruiting | Aspargo Labs | Jul 15, 2026 | 24 |
| NCT07300020Healthy Volunteer | 1 | Not yet recruiting | Aspargo Labs | Jun 15, 2026 | 24 |
| NCT07333742Fed Conditions · South Korea | 1 | Completed | LG Chem | Nov 27, 2025 | 50 |
| NCT07222098Healthy · United States | 1 | Completed | Merck | Dec 14, 2025 | 16 |
| NCT07121959Healthy · United States | 1 | Completed | Merck | Sep 13, 2025 | 14 |
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Apr 30, 2026 | 800 |
| NCT06823856Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | May 21, 2025 | 64 |
| NCT06792968Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Apr 6, 2025 | 64 |
| NCT07092618Longevity · United States | 3 | Recruiting | AgelessRx | Aug 2025 | 150 |
| NCT06766500Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Feb 28, 2025 | 64 |
| NCT06233201Healthy Subjects | 1 | Not yet recruiting | Bio-innova | Jul 14, 2024 | 34 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | AstraZeneca | Feb 5, 2024 | 20 |
| NCT05823883DW6014 · Korea, Republic of | 1 | UNKNOWN | Dong Wha Pharmaceutical | Jul 2023 | 30 |
| NCT05823870Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Mar 6, 2023 | 32 |
| NCT05874180Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Feb 1, 2023 | 31 |
| NCT05874167Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Oct 11, 2022 | 50 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05753371Drug Use · Indonesia | – | Completed | PT. Pyridam Farma Tbk | Mar 24, 2022 | 24 |
| NCT05463094Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Jan 3, 2023 | 84 |
| NCT05337969To Determine Bioequivalence Under Fed Conditions | – | Completed | AET Laboratories Private | Dec 2015 | 60 |
| NCT05329857To Determine Bioequivalence Under Fed Conditions | – | Completed | AET Laboratories Private | Jan 2016 | 60 |
| NCT05167513Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Apr 28, 2022 | 188 |
| NCT05132023Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 2, 2019 | 26 |
| NCT05124730Pharmacokinetics · Czechia | 1 | Completed | Joint Stock Company "Farmak" | May 29, 2021 | 44 |
| NCT05124717Pharmacokinetics · Czechia | 1 | Completed | Joint Stock Company "Farmak" | Jul 3, 2019 | 28 |
| NCT05123781Pharmacokinetics · Czechia | 1 | Completed | Joint Stock Company "Farmak" | Apr 17, 2019 | 28 |
| NCT05125575Pharmacokinetics · Czechia | 1 | Completed | Joint Stock Company "Farmak" | Jan 19, 2019 | 28 |
| NCT05064488Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 10, 2021 | 40 |
| NCT04899349Breast Neoplasms · United States, Malaysia | 2 | Terminated | Novartis | May 10, 2023 | 2 |
| NCT04855513Pre-Eclampsia · Qatar | – | UNKNOWN | Hamad Medical | Apr 24, 2023 | 414 |
| NCT04841096Diabetes Mellitus, Type 2 · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Mar 15, 2024 | 162 |
| NCT04684420Diabetes Mellitus · Korea, Republic of | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 11, 2022 | 81 |
| NCT04604678COVID-19 · United States | 2 | Withdrawn | AgelessRx | Aug 2021 | 0 |
| NCT04428086Solid Tumor, Adult · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 19 |
| NCT04317703Diabetes Mellitus, Type 2 · Thailand | 1 | Completed | LG Chem | Sep 5, 2020 | 40 |
| NCT04231435Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2020 | 24 |
| NCT04050098Type2 Diabetes | 1 | UNKNOWN | LG Chem | Nov 30, 2019 | 24 |
| NCT03880825Healthy Subjects · United States | 1 | Completed | Cortendo AB | May 3, 2019 | 32 |
| NCT03826602Drug-drug Interaction · United States | 1 | Completed | Pfizer | Mar 8, 2019 | 18 |
| NCT03593707Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Jan 17, 2019 | 18 |
| NCT03566810Diabetes Mellitus · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | Nov 28, 2018 | 54 |
| NCT03467971Healthy · Mexico | 1 | Completed | Merck KGaA, Darmstadt, Germany | Apr 22, 2018 | 21 |
| NCT03467945Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Apr 29, 2018 | 40 |
| NCT03458208Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation | 1 | Completed | Geropharm | Mar 2, 2017 | 18 |
| NCT03452306Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation | 1 | Completed | Geropharm | Jul 22, 2017 | 28 |
| NCT03393208Diabetes Mellitus · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | Jan 29, 2018 | 44 |
| NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil | 1 | Completed | AstraZeneca | May 22, 2018 | 284 |
| NCT03787017Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Aug 2014 | 36 |
How it is read
Names in the registry
- “Metformin”, 95 entries
- “metformin”, 33 entries
- “Metformin XR”, 11 entries
- “Fenofibrate /Metformin”, 6 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: EFB0027.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 162 studies
- Diabetes Mellitus, 17 studies
- Obesity, 3 studies
- Fasting, 3 studies
- Polycystic Ovary Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.